Flush with $1.5B from selling sevasemten, Edgewise bets the new company on whether EDG-7500 can carve space from aficamten in a crowded HCM market

Edgewise is a clinical-stage cardiovascular company developing EDG-7500, a targeted cardiac drug for hypertrophic cardiomyopathy, which is not yet approved.

Edgewise converted its muscular dystrophy program into $1.55B cash by selling sevasemten to Servier, then pivoted entirely to cardiovascular disease, concentrating value in EDG-7500, a cardiac myosin inhibitor for hypertrophic cardiomyopathy. The thesis resolves on whether Phase 3 EDG-7500 data demonstrate differentiation from aficamten, which already holds an HCM approval. The company is fully funded through potential approval, removing financing risk, but entering Phase 3 as a fast-follower behind an entrenched first-mover is the structural challenge.